EPHA2 and Ewing sarcoma: Differential expression analysis of 24 target genes for clinically available therapeutic antibodies, tyrosine kinase inhibitors, and proteasomal inhibitors demonstrated specific up-regulation of transcripts encoding ErbB3 in pediatric rhabdomyosarcomas, and transcripts encoding VEGF-C and EphA2 in Ewing’s sarcoma.